These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 29047301)

  • 1. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
    Sahli ZT; Tarazi FI
    Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
    Kianirad Y; Simuni T
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
    Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
    Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Chendo I; Ferreira JJ
    Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
    Mathis MV; Muoio BM; Andreason P; Avila AM; Farchione T; Atrakchi A; Temple RJ
    J Clin Psychiatry; 2017 Jun; 78(6):e668-e673. PubMed ID: 28493654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
    Panchal SC; Ondo WG
    Curr Psychiatry Rep; 2018 Jan; 20(1):3. PubMed ID: 29374325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
    Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
    Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pimavanserin: First Global Approval.
    Markham A
    Drugs; 2016 Jul; 76(10):1053-7. PubMed ID: 27262680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pimavanserin.
    Hunter NS; Anderson KC; Cox A
    Drugs Today (Barc); 2015 Nov; 51(11):645-52. PubMed ID: 26744739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
    Hacksell U; Burstein ES; McFarland K; Mills RG; Williams H
    Neurochem Res; 2014 Oct; 39(10):2008-17. PubMed ID: 24682754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
    McFarland K; Price DL; Bonhaus DW
    Behav Pharmacol; 2011 Oct; 22(7):681-92. PubMed ID: 21921840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
    Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
    Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.
    Lyons KE; Pahwa R; Hermanowicz N; Davis T; Pagan F; Isaacson S
    Expert Rev Clin Pharmacol; 2019 Jul; 12(7):681-691. PubMed ID: 31159608
    [No Abstract]   [Full Text] [Related]  

  • 14. Pimavanserin for the treatment of Parkinson's disease psychosis.
    Friedman JH
    Expert Opin Pharmacother; 2013 Oct; 14(14):1969-75. PubMed ID: 24016069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
    Ballard CG; Kreitzman DL; Isaacson S; Liu IY; Norton JC; Demos G; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
    Parkinsonism Relat Disord; 2020 Aug; 77():100-106. PubMed ID: 32712560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial of Pimavanserin in Dementia-Related Psychosis.
    Tariot PN; Cummings JL; Soto-Martin ME; Ballard C; Erten-Lyons D; Sultzer DL; Devanand DP; Weintraub D; McEvoy B; Youakim JM; Stankovic S; Foff EP
    N Engl J Med; 2021 Jul; 385(4):309-319. PubMed ID: 34289275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L; Norton JC; Chi-Burris K; Demos G
    CNS Spectr; 2018 Jun; 23(3):228-238. PubMed ID: 29098976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
    Isaacson SH; Ballard CG; Kreitzman DL; Coate B; Norton JC; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
    Parkinsonism Relat Disord; 2021 Jun; 87():25-31. PubMed ID: 33933853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
    Nasrallah HA; Fedora R; Morton R
    Schizophr Res; 2019 Jun; 208():217-220. PubMed ID: 30837203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimavanserin evaluated by the FDA.
    Webster P
    Lancet; 2018 May; 391(10132):1762. PubMed ID: 29739555
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.